There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cassava Sciences (SAVA – Research Report) and Concert Pharma (CNCE – Research Report) with bullish sentiments. Cassava Sciences (SAVA) H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cassava Sciences today and set a price target of $124.00. The company's shares closed last Thursday at $20.26, close to its 52-week low of $18.07. According to TipRanks.
https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-140?utm_source=advfn.com&utm_medium=referral
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Cassava Sciences Charts.